Payment overview · 2025
General Payments
$222.48
10 reported records · 2 companies
Healthcare provider profile · identity verified
Subhash K Reddy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · FORT WAYNE, IN · NPI 1821068511
Verified facts
What the public records show
CMS Open Payments records show Subhash K Reddy, M.D. received $222.48 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 76.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 414 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $169.76 | 76.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.72 | 23.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $222.48 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $111.83 | 5 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $82.88 | 4 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $82.27 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.72 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $52.72 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $36.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 414 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
414 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 662 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 59 |
| Memantine Hcl | Memantine Hcl | 488 | 70 |
| Sertraline Hcl | Sertraline Hcl | 433 | 91 |
| Eliquis | Apixaban | 414 | 47 |
| Gabapentin | Gabapentin | 324 | 62 |
| Metformin Hcl | Metformin Hcl | 316 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 314 | 37 |
| Gemtesa | Vibegron | 306 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 47 |
| Divalproex Sodium | Divalproex Sodium | 221 | 44 |
| Trazodone Hcl | Trazodone Hcl | 217 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 33 |
| Olanzapine | Olanzapine | 194 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 191 | 32 |
| Losartan Potassium | Losartan Potassium | 173 | 38 |
| Carvedilol | Carvedilol | 170 | 30 |
| Furosemide | Furosemide | 161 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 31 |
| Levetiracetam | Levetiracetam | 158 | 24 |
| Omeprazole | Omeprazole | 158 | 29 |
| Lisinopril | Lisinopril | 156 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 36 |
| Risperidone | Risperidone | 143 | 31 |
| Jardiance | Empagliflozin | 130 | 14 |
| Tradjenta | Linagliptin | 124 | suppressed |
| Clozapine | Clozapine | 118 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 21 |
| Potassium Chloride | Potassium Chloride | 107 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 17 |
| Invega Sustenna | Paliperidone Palmitate | 99 | 18 |
| Famotidine | Famotidine | 96 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 94 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 33 |
| Spironolactone | Spironolactone | 78 | 16 |
| Lithium Carbonate | Lithium Carbonate | 74 | suppressed |
| Allopurinol | Allopurinol | 70 | suppressed |
| Mirtazapine | Mirtazapine | 70 | 22 |
| Lamotrigine | Lamotrigine | 64 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 30 |
| Clonidine Hcl | Clonidine Hcl | 62 | 17 |
| Finasteride | Finasteride | 62 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 16 |
| Midodrine Hcl | Midodrine Hcl | 56 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | suppressed |
| Risperidone Er | Risperidone Microspheres | 54 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 16 |
| Meloxicam | Meloxicam | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 16 |
| Latanoprost | Latanoprost | 51 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 32 |
| Insulin Lispro | Insulin Lispro | 48 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | 16 |
| Aptiom | Eslicarbazepine Acetate | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Micafungin | Micafungin Sodium | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Anastrozole | Anastrozole | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 33 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 11 |
| Glipizide | Glipizide | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Acetazolamide | Acetazolamide | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 11 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Paliperidone Er | Paliperidone | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Risperdal Consta | Risperidone Microspheres | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 16 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 15 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 11 |
| Insulin Aspart | Insulin Aspart | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 14 | 11 |
| Nystop | Nystatin | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | 11 |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $222.48 · 10 records | ABBVIE INC. | AVYCAZ, DALVANCE, ELIQUIS, EMBLAVEO, PAXLOVID, TEFLARO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error